DNX-2401 is an oncolytic immunotherapy designed to fulfill the dual requirements of high potency and safety. To accomplish this, two stable genetic changes in the adenovirus genome were engineered that cause it to replicate selectively in retinoblastoma (Rb) pathway deficient cells and infect tumor cells efficiently. Results from pre-clinical and clinical studies indicate that DNX-2401 (1) replicates in human tumors (2) elicits tumor necrosis (3) triggers intratumoral immune cell infiltration, and (4) can lead to long term tumor destruction. DNX-2401 has been granted Fast Track and Orphan designation by the FDA.
Armed with OX40L
DNX-2440 is the first Armed DNX virus in development for solid tumors. It combines the clinically effective and safe viral backbone of the DNX technology with the expression of a potent immune-modulator, OX40 ligand (OX40L). OX40 is a member of the tumor necrosis factor receptor superfamily, and interactions between OX40 and OX40L act as co-stimulatory signals for T-cell activation. The augmentation of this interaction enhances antitumor immunity.
Armed with undisclosed t-cell stimulator
DNX-2450, is an Armed DNX virus in development for solid tumors. It combines the clinically effective and safe viral backbone of the DNX technology with the expression of an undisclosed T-cell stimulator that can enhance antitumor immunity.